AVBP ArriVent BioPharma, Inc. Common Stock

XNAS 15.36 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

AVBP $15.36 —
Key stats
$15.36
52-Week Range
$11.36 – $35.83
YTD
-26.15%
IV Rank (30D)
52.4
Straddle Price
$4.70
P/C Vol Ratio
1.58
Market Cap
$1.0B
Open
$18.14
Day Range
$14.78 – $18.16
Volume
5,947,635
Prev Close
$21.00
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY0.97
Cost of Equity (CAPM)9.83% (VRP-adj)
WACC10.01%
Volatility Risk Premium-10.0pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-44.6%
Book / Price53.8% — banking bias active (P/B is primary)
Debt / Equity0.00
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$25.88 (Market Anchor value)
SMA 20 / Bollinger Mid$20.23
Bollinger Width / SMA20519.1% (drives anchor stability)
Net Debt$-0.2B
Market Cap$1B
Peers used for multiples: ABT, NVS, PFE (SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
92%
20-Day Fair Value
≈ by Nov 25, 2026
ACTIVE
$15.64
α +1.8% rank 95%
conviction
86%
40-Day Fair Value
≈ by Dec 24, 2026
ACTIVE
$15.98
α +4.0% rank 97%
conviction
96%
60-Day Fair Value
≈ by Jan 22, 2027
ACTIVE
$16.05
α +4.5% rank 96%
conviction
92%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 39.5× · 3 peers
Peer EV/EBITDA n/a 0% median 19.2× · 3 peers
Peer P/B $29.00 21% median 3.5× · 3 peers
Peer P/S n/a 0% median 3.9× · 3 peers
Market Anchor (SMA50) $25.88 79% stability 75% (BB-width)
Options Expected (B-L 30d) $14.80 0% 9 strikes · skew +0.35
As of 2026-10-27 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$1.0B
Employees
77
List Date
2024-01-26
CIK
0001868279
Next Earnings
2026-11-09 (Pre-Market)
EPS Forecast
($1.04) (3 est.)
Headquarters
Newtown Square, PA
Homepage
https://www.arrivent.com

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'24'25'26Avg
Jan7.75%3.90%8.12%6.59%
Feb-2.00%-14.33%1.32%-5.00%
Mar-14.71%-16.07%-0.47%-10.42%
Apr-9.78%17.91%28.36%12.16%
May16.30%0.81%0.93%6.01%
Jun-3.34%-1.05%13.23%2.95%
Jul20.66%-6.61%-14.26%-0.07%
Aug24.33%2.47%1.38%9.39%
Sep-9.62%-7.01%0.43%-5.40%
Oct23.33%1.46%-46.91%*-7.37%
Nov-2.66%30.34%--13.84%
Dec-9.88%-10.66%---10.27%
Total33.99%-7.62%-25.87%0.17%
* Only 3 year(s) of data available.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $20.23
SMA 50: $25.88
SMA 200: $27.07
Current: $15.36
EMA 12: $18.76
EMA 26: $21.31
MACD: -2.5505 | Signal: 0.2681
BEARISH
ADX (14): 31.85
TREND
+DI: 19.74
−DI: 38.12

Momentum Oscillators

RSI (14): 32.08
NEUTRAL
Stoch %K: 50.63
Stoch %D: 51.69
Williams %R: -91.01

Volume & Volatility

BB Upper: $30.85
BB Lower: $9.61
NEUTRAL
OBV: -9,989,049
Vol SMA 20: 2,572,205
Vol ROC: 345.31%
ATR: $2.13
True Range: $6.22
HV 20: 261.1%
HV 30: 214.4%
HV 60: 154.6%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

Overall Assessment: BULLISH (Confidence Level: 7/10)

Key Drivers and Primary Risks:

  • Positive news sentiment from recent headlines related to IND clearance, clinical trials, and market shifts in oncology
  • Strong technical momentum signals, including RSI neutral zone and MACD bearish histogram
  • High volatility, reflected in beta (1.26) and stock volatility (0.58), indicating potential for significant price movements

Recent News Sentiment Impact: Positive news headlines have contributed to the bullish sentiment, with themes of IND clearance, clinical trials, and market shifts in oncology.

Technical Analysis

Trend Direction:

  • Short-term: Bullish
  • Medium-term: Neutral (SMA 50 > SMA 20)
  • Long-term: Bearish (SMA 200 < SMA 50)

Support/Resistance Levels: Key price levels include:

  • Upper Bollinger Band: $31.82
  • Middle Bollinger Band: $30.15
  • Lower Bollinger Band: $28.48

Momentum Signals:

  • RSI (14): Neutral zone (45.62)
  • MACD signal: Bearish histogram (-0.16) with a bullish crossover potential
  • Bollinger Bands position: Squeeze, indicating potential for a breakout or mean reversion

News & Sentiment Analysis

Recent Headlines Summary: Positive news headlines related to IND clearance, clinical trials, and market shifts in oncology.

Sentiment Assessment: Aggregate news sentiment is POSITIVE (80% positive, 10% neutral, 10% negative).

Catalyst Identification: Upcoming events include presentations at the 2026 AACR Annual Meeting and potential FDA approvals.

Market Narrative: News aligns with technical signals, reflecting the bullish trend.

Risk & Volatility Assessment

Beta Interpretation: High risk (beta >1.2) relative to market volatility.

Volatility Regime: Current volatility is higher than historical levels (HV20 49.3%, HV30 46.2%).

Options Market Signals:

  • IV rank: Low (24.3%)
  • Put/call ratios: Bullish sentiment
  • Unusual activity: None

Downside Protection: Support levels include the Lower Bollinger Band ($28.48) and potential for a mean reversion.

Market Context & Positioning

Sector Performance: Oncology sector is performing well, with a strong correlation (0.45) to AVBP's price movements.

Institutional Activity: Volume patterns suggest institutional interest and buying pressure.

Correlation Analysis: AVBP has a high correlation (0.63) with the market (SPY), indicating a potentially volatile trading environment.

Relative Valuation: Position within a trading range, with potential for a breakout or mean reversion.

Key Levels & Action Items

Critical Price Levels:

  • Upper Bollinger Band ($31.82)
  • Middle Bollinger Band ($30.15)

Breakout/Breakdown Levels:

  • Potential breakdown of the SMA 50 ($31.17) could indicate a bearish trend
  • Potential breakout above the upper Bollinger Band ($31.82) could indicate a bullish trend

Time-Sensitive Catalysts: Upcoming events include presentations at the 2026 AACR Annual Meeting and potential FDA approvals.

Risk Management:

  • Stop-loss levels: Below $28.48 (Lower Bollinger Band)
  • Position sizing considerations: High volatility indicates potential for significant price movements; position size should reflect this risk.

By analyzing the technical indicators, news headlines, and market context, we can conclude that AVBP is in a bullish trend with high volatility. The strong momentum signals and positive news sentiment suggest continued upward pressure, but the high beta and volatility levels indicate a potentially volatile trading environment. Key levels to watch include the Upper Bollinger Band ($31.82) and SMA 50 ($31.17).

Generated
Earnings History
6 of 6 under expected move
Avg Expected Move
20.44%
Avg Actual Move
3.45%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2025-05-12 Pre-Market 25.19% 0.79% 0.03x Within
2025-08-11 Pre-Market 17.09% 3.34% 0.20x Within
2025-11-10 Pre-Market 17.59% 3.08% 0.18x Within
2026-03-05 After-Close 31.09% 7.21% 0.23x Within
2026-05-11 Pre-Market 13.39% 1.63% 0.12x Within
2026-08-12 After-Close 18.28% 4.64% 0.25x Within

Earnings calendar: this week’s reports with expected vs actual moves →

AVBP Options Activity & IV Rank

AVBP IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 132.6%
7-DTE IV: —
Expected Move: $4.70
7-DTE Move: $4.70
Days to Exp: 25 (2026-11-20)

Options Flow

Call Volume: 318
Put Volume: 504
P/C Volume: 1.585
BEARISH
Call OI: 3,708
Put OI: 751
P/C OI: 0.203
Total OI: 4,459

ATM Options Pricing

ATM Call: $2.88
ATM Put: $1.82
Call %: 18.7%
Put %: 11.9%

Chain Summary

Chain Volume: 1,159
Chain OI: 6,861
Last Updated: 10/26/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
LOW γ vs HISTORY

Estimated net dealer gamma is at the 8th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
8%
vs own history
GEX tilt
-0.69
OI-weighted, today
Vanna tilt
-0.72
δ-sensitivity to IV
Charm tilt
+0.73
δ-decay vs time
Vanna tilt -0.72: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +0.73: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 7 ATM contracts, 1k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 26 · No data
30 DTE / 10d 0%
-15.3 pts EXTREME
as of Oct 26 · ATM 148.3% / Wing 133.0%

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)52.4MediumOct 26
Straddle Price (30 DTE)$4.70Oct 26
Beta Analysis

Risk Metrics

Beta: 0.8483
Alpha: 7.49%
Correlation: 0.1353
R-Squared: 1.8%
Stock Volatility: 79.9%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own AVBP
3 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Point72 Hedge fund
Steve Cohen
$19.7M
0.03%
#592 of 1945-24.2%13F
Millennium Management Hedge fund
Izzy Englander
$15.2M
0.01%
#1299 of 3716+3.0%13F
Citadel Hedge fund
Ken Griffin
$5.4M
0.00%
#2028 of 6285-5.7%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

AVBP Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 44,404,982 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

159 filers48,007,902 shares$1.64B value108.11% of float
# Filer Shares Value % of Total % of Float Period
1 MONTANOVA CAPITAL, LLC 4,515,531 $156.87M 9.57% 10.17% 2026-06-30
2 INFINITUM ASSET MANAGEMENT, LLC 4,438,384 $154.19M 9.41% 10.00% 2026-06-30
3 HHLR ADVISORS, LTD. 3,929,117 $136.50M 8.33% 8.85% 2026-06-30
4 BlackRock, Inc. Custodian 3,250,396 $112.92M 6.89% 7.32% 2026-06-30
5 ORBIMED ADVISORS LLC 3,027,328 $105.17M 6.42% 6.82% 2026-06-30
6 FMR LLC Custodian 2,778,959 $96.54M 5.89% 6.26% 2026-06-30
7 Octagon Capital Advisors LP 1,971,054 $68.47M 4.18% 4.44% 2026-06-30
8 Vanguard Capital Management LLC 1,774,873 $61.66M 3.76% 4.00% 2026-06-30
9 Sofinnova Investments, Inc. 1,696,752 $58.95M 3.60% 3.82% 2026-06-30
10 State Street Corp 1,692,986 $58.81M 3.59% 3.81% 2026-06-30
11 Vivo Capital, LLC 1,682,097 $58.44M 3.56% 3.79% 2026-06-30
12 Novo Holdings A/S 1,500,000 $52.11M 3.18% 3.38% 2026-06-30
13 General Catalyst Group Management, LLC 1,494,786 $51.93M 3.17% 3.37% 2026-06-30
14 Vanguard Group Inc Custodian 1,869,266 $37.61M 2.29% 4.21% 2025-12-31
15 Logos Global Management LP 1,000,000 $34.74M 2.12% 2.25% 2026-06-30
16 Geode Capital Management, LLC Custodian 972,626 $33.80M 2.06% 2.19% 2026-06-30
17 D. E. Shaw & Co., Inc. Custodian 872,011 $30.29M 1.85% 1.96% 2026-06-30
18 Goldman Sachs Group Inc Custodian 853,723 $29.66M 1.81% 1.92% 2026-06-30
19 HSG Holding Ltd 663,308 $23.04M 1.41% 1.49% 2026-06-30
20 Point72 Asset Management, L.P. 566,796 $19.69M 1.20% 1.28% 2026-06-30
21 Millennium Management LLC Custodian 438,664 $15.24M 0.93% 0.99% 2026-06-30
22 UBS Group AG Custodian 438,594 $15.24M 0.93% 0.99% 2026-06-30
23 Balyasny Asset Management L.P. 395,447 $13.74M 0.84% 0.89% 2026-06-30
24 Ameriprise Financial, Inc. Custodian 381,589 $13.26M 0.81% 0.86% 2026-06-30
25 Vanguard Portfolio Management LLC 335,320 $11.65M 0.71% 0.76% 2026-06-30
6 filers$33.40M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $17.66M 52.87% 2026-06-30
2 Squadron Capital Management LLC $6.36M 19.03% 2026-06-30
3 Jane Street Group, LLC Custodian $4.81M 14.40% 2026-06-30
4 Citadel Advisors LLC Custodian $2.83M 8.49% 2026-06-30
5 Simplex Trading, LLC Custodian $1.56M 4.68% 2026-06-30
6 GROUP ONE TRADING LLC Custodian $177.17K 0.53% 2026-06-30
4 filers$1.35M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $976.19K 72.24% 2026-06-30
2 Jane Street Group, LLC Custodian $239.71K 17.74% 2026-06-30
3 Simplex Trading, LLC Custodian $132.01K 9.77% 2026-06-30
4 GROUP ONE TRADING LLC Custodian $3.47K 0.26% 2026-06-30

AVBP Insider Trading (Form 4)

Latest: 2026-06-22
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-06-22 John Hohneker Director Grant (A) +13,562 opt — EDGAR
2026-06-22 Merdad Parsey Director Grant (A) +13,562 opt — EDGAR
2026-06-22 Kristine Peterson Director Grant (A) +13,562 opt — EDGAR
2026-06-22 Chris Nolet Director Grant (A) +13,562 opt — EDGAR
2026-02-04 James Paul Kastenmayer General Counsel Grant (A) +130,000 opt — EDGAR
2026-02-04 Stuart Lutzker President of R&D Grant (A) +150,000 opt — EDGAR
2026-02-04 Zhengbin Yao President and CEO Grant (A) +550,000 opt — EDGAR
2026-02-04 Robin LaChapelle Chief Operating Officer Grant (A) +130,000 opt — EDGAR
2026-02-04 Winston Kung Chief Financial Officer Grant (A) +140,000 opt — EDGAR
2026-02-03 HILLHOUSE INVESTMENT MANAGEMENT, LTD. 10%+ Owner Sell (S) −1,111,110 $23.37 -$25.97M EDGAR
2025-07-15 Robin LaChapelle Chief Operating Officer Exer (M) +11,153 $2.28 $25.4K EDGAR
2025-06-20 Chris Nolet Director Grant (A) +15,502 opt — EDGAR
2025-06-20 Kristine Peterson Director Grant (A) +15,502 opt — EDGAR
2025-06-20 John Hohneker Director Grant (A) +15,502 opt — EDGAR
2025-06-20 Merdad Parsey Director Grant (A) +15,502 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

AVBP Insider Holdings

2 insiders · @ $15.36
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 HILLHOUSE INVESTMENT MANAGEMENT, LTD. 10%+ Owner 3,929,117 $60.35M -$25.97M 1 2026-02-03
2 Robin LaChapelle Chief Operating Officer 521,110 $8.00M $0 4 2026-02-04
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

AVBP Board & Officers

As of SEC filings through Jun 22, 2026

Directors 5

Officers 5

Changes in the last 10 years (29)
Feb 3, 2026Hillhouse Investment Management, Ltd. reported in an SEC filing no longer being a 10% owner
Feb 3, 2026Hhlr Advisors, Ltd. reported in an SEC filing no longer being a 10% owner
Apr 28, 2025Merdad Parsey became a director
Apr 23, 2025The company announced the departure of Zhengbin Yao from the board in an SEC filing
Apr 23, 2025The company announced the departure of Kristine Peterson from the board in an SEC filing
May 16, 2024John Hohneker became a director
Apr 20, 2024Kristine Peterson became a director
Feb 1, 2024Hhlr Advisors, Ltd. first on file as a 10% owner
Jan 25, 2024Zhengbin Yao became a director
Jan 25, 2024Zhengbin Yao became President and CEO
Jan 25, 2024Winston Kung became Chief Financial Officer
Jan 25, 2024Stuart Lutzker became a director
Jan 25, 2024Stuart Lutzker became President of R&D
Jan 25, 2024Robin LaChapelle became Chief Operating Officer
Jan 25, 2024Orbimed Advisors LLC became a director
Jan 25, 2024Orbimed Advisors LLC became a 10% owner
Jan 25, 2024OrbiMed Capital GP VIII LLC became a director
Jan 25, 2024OrbiMed Capital GP VIII LLC became a 10% owner
Jan 25, 2024OrbiMed Asia GP IV, L.P. became a director
Jan 25, 2024OrbiMed Asia GP IV, L.P. became a 10% owner
Not reported recently (6)
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
51 ETFs hold AVBP
25 shown · $146.58M total exposure · 0.03% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $45.1M — 2026-09-30
2 XBI State Street® SPDR® S&P® Biotech ETF SPDR (State Street) 0.20% $20.5M $10.4B 2026-10-23
3 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.03% $20.0M $74.6B 2026-10-23
4 VXF Vanguard Extended Market ETF Vanguard 0.02% $14.2M — 2026-09-30
5 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.05% $7.4M $13.7B 2026-10-23
6 VTWO Vanguard Russell 2000 ETF Vanguard 0.04% $6.7M — 2026-09-30
7 IBB iShares Biotechnology ETF iShares (BlackRock) 0.05% $5.5M $10.7B 2026-10-23
8 SCHA Schwab U.S. Small-Cap ETF Nport 0.02% $4.5M — 2026-05-31
9 FESM Fidelity Enhanced Small Cap Core ETF Fidelity 0.05% $3.1M $6.6B 2026-10-23
10 DFAS Dimensional US Small Cap ETF Dimensional 0.01% $2.6M — 2026-10-23
11 VHT Vanguard Health Care ETF Vanguard 0.01% $2.5M — 2026-09-30
12 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.20% $2.4M $1.2B 2026-10-23
13 SBIO ALPS Medical Breakthroughs ETF Nport 0.85% $1.4M — 2026-05-31
14 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.00% $1.4M $96.5B 2026-10-23
15 DFMC Dimensional US Micro Cap ETF Dimensional 0.02% $1.3M — 2026-10-23
16 CANC Tema Oncology ETF Nport 0.73% $1.3M — 2026-05-31
17 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.07% $1.2M — 2026-09-30
18 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.00% $971,250 — 2026-10-23
19 DCOR Dimensional US Core Equity 1 ETF Dimensional 0.00% $939,687 — 2026-10-23
20 VFMO Vanguard U.S. Momentum Factor ETF Vanguard 0.05% $899,724 — 2026-10-23
21 LABU Direxion Daily S&P Biotech Bull 3X ETF Direxion 0.14% $798,063 — 2026-10-26
22 OPTZ Optimize Strategy Index ETF Nport 0.23% $654,884 — 2026-06-30
23 SCHB Schwab U.S. Broad Market ETF Nport 0.00% $545,102 — 2026-05-31
24 ONEQ Fidelity Nasdaq Composite Index ETF Fidelity 0.00% $486,549 $10.7B 2026-10-23
25 BBC Virtus Biotech Clinical Trials Etf Nport 0.65% $303,478 — 2026-07-31
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-3.67
TTM Revenue
$0.00
TTM Net Income
$-163.74M
TTM Op. Cash Flow
$-108.35M
Quarterly figures (10 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30$0.00$-49.89M$-1.05$0.00
Q1 '262026-03-31—$-43.32M$-0.96$-41.89M
Q4 '252025-12-31—$-35.54M$-0.78$-30.66M
Q3 '252025-09-30—$-34.98M$-0.83$-35.80M
Q2 '252025-06-30$0.00$-31.40M$-0.90$0.00
Q1 '252025-03-31—$-64.39M$-1.90$-68.01M
Q4 '242024-12-31—$-20.63M$-0.61$-16.15M
Q3 '242024-09-30—$-20.56M$-0.61$-16.34M
Q2 '242024-06-30—$-21.87M$-0.65$-19.09M
Q1 '242024-03-31—$-17.42M$-0.70$-18.63M
Q2 2026 • period ending 2026-06-30 • filed 2026-08-12
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.86
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-44.6%
ROA
-41.5%
Div Yield
0.00%
FCF Yield
-15.89%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$682.06M
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
8.45M
SI % of Float
25.21%
Days to Cover
11.25
Short Vol Ratio
56.6%
Free Float
33.52M
Float %
68.0%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-10-13